Press Room

Sansum Diabetes Research Institute, University of California, Santa Barbara Conduct Innovative Artificial Pancreas – Ultra-Rapid-Acting Inhaled Insulin Trial Funded by JDRF

JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin. 


JDRF Honors Researchers Whose Insights on Early Type 1 Diabetes Development Have Set the Stage for Disease Prevention in Children

The three winners of JDRF’s 2013  Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award have provided critical insights into the type 1 diabetes disease process in young children, laying the groundwork for targeted disease prevention strategies


JDRF Canada Opens the Market

On Friday, September 20, Dave Prowten, President & CEO, JDRF Canada, and Charlotte Romain, Youth Ambassador, JDRF Canada joined Eleanor Fritz, Director, Compliance & Disclosure, Toronto Stock Exchange to open the market and raise awareness of the 25th annual ...


JDRF Canada Announces New President and CEO

On behalf of the JDRF Canada Board of Directors, we are pleased to announce the appointment of Dave Prowten as the new President and Chief Executive Officer of JDRF Canada.


Giving diabetes the boot

Sun Life Financial launches diabetes program to support preventative research across Canada


JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems

JDRF announced today partnerships with both Xeris Pharmaceuticals, Inc., and LATITUDE Pharmaceuticals, Inc. (LPI), to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal ...


JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes

JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) are accelerating the development of new products that combine BD’s proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today.


Run or Walk in Support of JDRF Canada at the Barrie Waterfront Half Marathon

TORONTO (June 14, 2013) – On Sunday, June 16, 2013, the third annual Barrie Waterfront Half Marathon, 10K & 5K is taking place throughout the streets of Barrie and along scenic Lake Simcoe. New for 2013 is the partnership with JDRF, where runners and walkers can ...


iCo Therapeutics and JDRF Partnership Goes Beyond Clinical Advancement

VANCOUVER (June 5, 2013) - iCo and JDRF established a partnership in September 2011 when they joined forces on the iDEAL Study to improve outcomes for people affected by diabetic macular edema (DME).


JDRF Canada Responds to Chapter 5 of the 2013 Spring Report of the Auditor General of Canada: Promoting Diabetes Prevention and Control

TORONTO (May 2, 2013) – JDRF Canada welcomes the recommendations brought forward in Chapter 5 of the 2013 Spring Report of the Auditor General of Canada:  Promoting Diabetes Prevention and Control.  This report can alternatively help change the face of diabetes in Canada.


Lets turn type one into type none